ROIVANT SCIENCES LTD. Increase (Decrease) in Deferred Revenue
ROIVANT SCIENCES LTD. (ROIV) reported Increase (Decrease) in Deferred Revenue of -$3.86 million for the 6-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2022-11-14
- ROIVANT SCIENCES LTD. increase (decrease) in deferred revenue for the quarter ending 2022-09-30 was -$2.13M, a 447.96% decline year-over-year.
- ROIVANT SCIENCES LTD. increase (decrease) in deferred revenue for the quarter ending 2022-06-30 was -$1.73M.
- ROIVANT SCIENCES LTD. increase (decrease) in deferred revenue for the quarter ending 2021-09-30 was $613.00K.
- ROIVANT SCIENCES LTD. increase (decrease) in deferred revenue for the quarter ending 2021-06-30 was -$2.14M.
- ROIVANT SCIENCES LTD. increase (decrease) in deferred revenue for fiscal 2022 was $17.97M, a 682.28% increase from fiscal 2021.
- ROIVANT SCIENCES LTD. increase (decrease) in deferred revenue for fiscal 2021 was $2.30M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|
| 2022-09-30 | -$2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | -$3.86M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$1.73M 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | $17.97M 10-K · filed 2022-06-28 | ||
| 2021-09-30 | $613.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | -$1.53M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$2.14M 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $2.30M 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |